ATE438399T1 - Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4- (2-carbamoylbenzofuran-5-yl)piperazin und dessem physiologisch akzeptablen salzen - Google Patents

Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4- (2-carbamoylbenzofuran-5-yl)piperazin und dessem physiologisch akzeptablen salzen

Info

Publication number
ATE438399T1
ATE438399T1 AT06017231T AT06017231T ATE438399T1 AT E438399 T1 ATE438399 T1 AT E438399T1 AT 06017231 T AT06017231 T AT 06017231T AT 06017231 T AT06017231 T AT 06017231T AT E438399 T1 ATE438399 T1 AT E438399T1
Authority
AT
Austria
Prior art keywords
carbamoylbenzofuran
cyanoindol
piperazine
butyl
acceptable salts
Prior art date
Application number
AT06017231T
Other languages
German (de)
English (en)
Inventor
Gerd Bartoszyk
Christoph Seyfried
Amsterdam Christoph Van
Henning Boettcher
Ewen Sedman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE438399(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE438399T1 publication Critical patent/ATE438399T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06017231T 1999-05-27 2000-05-16 Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4- (2-carbamoylbenzofuran-5-yl)piperazin und dessem physiologisch akzeptablen salzen ATE438399T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99109295 1999-05-27

Publications (1)

Publication Number Publication Date
ATE438399T1 true ATE438399T1 (de) 2009-08-15

Family

ID=8238153

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06017231T ATE438399T1 (de) 1999-05-27 2000-05-16 Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4- (2-carbamoylbenzofuran-5-yl)piperazin und dessem physiologisch akzeptablen salzen
AT04001441T ATE337008T1 (de) 1999-05-27 2000-05-16 Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4- (2-carbamoylbenzofuran-5-yl)piperazin und deren physiologisch akzeptablen salzen
AT00935031T ATE263564T1 (de) 1999-05-27 2000-05-16 Verwendung von 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylben ofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT04001441T ATE337008T1 (de) 1999-05-27 2000-05-16 Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4- (2-carbamoylbenzofuran-5-yl)piperazin und deren physiologisch akzeptablen salzen
AT00935031T ATE263564T1 (de) 1999-05-27 2000-05-16 Verwendung von 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylben ofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie

Country Status (31)

Country Link
US (4) US6900212B1 (enExample)
EP (3) EP1410800B1 (enExample)
JP (2) JP4884588B2 (enExample)
KR (1) KR100683367B1 (enExample)
CN (3) CN1198618C (enExample)
AR (1) AR024112A1 (enExample)
AT (3) ATE438399T1 (enExample)
AU (1) AU771778B2 (enExample)
BR (1) BR0010948A (enExample)
CA (3) CA2372668C (enExample)
CY (2) CY1105750T1 (enExample)
CZ (1) CZ295623B6 (enExample)
DE (3) DE60009697T2 (enExample)
DK (3) DK1410800T3 (enExample)
ES (3) ES2271707T3 (enExample)
HK (1) HK1048444B (enExample)
HU (1) HU229059B1 (enExample)
IL (2) IL146707A0 (enExample)
MX (1) MXPA01012172A (enExample)
MY (1) MY135627A (enExample)
NO (2) NO322120B1 (enExample)
PL (3) PL200490B1 (enExample)
PT (3) PT1185272E (enExample)
RU (1) RU2237477C2 (enExample)
SI (2) SI1410800T1 (enExample)
SK (1) SK287851B6 (enExample)
TR (1) TR200103361T2 (enExample)
TW (1) TW518218B (enExample)
UA (1) UA74337C2 (enExample)
WO (1) WO2000072832A2 (enExample)
ZA (1) ZA200110485B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (de) * 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10305739A1 (de) 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
US20040192730A1 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
AU2007266890B2 (en) 2006-05-30 2011-02-17 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors
CA2707660A1 (en) 2007-12-20 2009-07-02 Astrazeneca Ab Carbamoyl compounds as dgat1 inhibitors 190
MX2011014018A (es) 2009-06-19 2012-02-22 Astrazeneca Ab Pirazincarboxamidas como inhibidores de dgati.
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
EP2688884A1 (en) 2011-03-20 2014-01-29 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
EP2861586A4 (en) 2012-06-13 2015-11-11 Apotex Inc FORMS OF VILAZODONE AND METHODS OF PREPARATION THEREOF
CN102860993A (zh) * 2012-10-16 2013-01-09 北京诚创思达医药科技有限公司 一种盐酸维拉唑酮快速释放片剂及其制备方法
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
EP3598971B1 (en) 2013-01-22 2024-03-20 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
EP3297619B1 (en) * 2015-05-22 2022-07-06 Vistagen Therapeutics, Inc. Therapeutic uses of l-4-chlorokynurenine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5914394A (en) * 1997-03-27 1999-06-22 Millenium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) * 1998-03-09 2002-10-29 Pirelli Pneumatici S.P.A. Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1291660A3 (en) * 2001-09-11 2003-05-28 Koyo Seiko Co., Ltd. Magnetic pulser ring, magnetizing device and method, and bearing unit having a magnetic pulser ring
FR2844591B1 (fr) * 2002-09-13 2005-04-15 Arvinmeritor Light Vehicle Sys Dispositif de determination du deplacement d'un arbre

Also Published As

Publication number Publication date
CA2694866A1 (en) 2000-12-07
SI1410800T1 (sl) 2007-02-28
CA2372668A1 (en) 2000-12-07
EP1736158A2 (en) 2006-12-27
AR024112A1 (es) 2002-09-04
UA74337C2 (uk) 2005-12-15
US20100063062A1 (en) 2010-03-11
SK287851B6 (sk) 2012-01-04
NO20015746D0 (no) 2001-11-26
SK16462001A3 (sk) 2002-02-05
US7642261B2 (en) 2010-01-05
NO324230B1 (no) 2007-09-10
PT1410800E (pt) 2007-01-31
TW518218B (en) 2003-01-21
EP1410800A1 (en) 2004-04-21
ES2271707T3 (es) 2007-04-16
US7371756B2 (en) 2008-05-13
DE60042710D1 (de) 2009-09-17
DE60009697T2 (de) 2005-04-14
CN1198618C (zh) 2005-04-27
DE60009697D1 (de) 2004-05-13
EP1736158B1 (en) 2009-08-05
PT1185272E (pt) 2004-08-31
CN1679577A (zh) 2005-10-12
NO20061562L (no) 2001-11-26
JP4884588B2 (ja) 2012-02-29
IL146707A (en) 2007-06-03
DK1185272T3 (da) 2004-08-09
US20080119484A1 (en) 2008-05-22
CY1105750T1 (el) 2010-12-22
CA2615271C (en) 2011-02-15
JP2011148799A (ja) 2011-08-04
HU229059B1 (en) 2013-07-29
JP2003500441A (ja) 2003-01-07
DE60030338T2 (de) 2007-08-16
AU5066300A (en) 2000-12-18
TR200103361T2 (tr) 2002-05-21
DE60030338D1 (de) 2006-10-05
CZ295623B6 (cs) 2005-09-14
WO2000072832A2 (en) 2000-12-07
PL352373A1 (en) 2003-08-25
NO322120B1 (no) 2006-08-14
ZA200110485B (en) 2003-06-30
HK1048444B (zh) 2005-12-09
DK1736158T3 (da) 2009-11-02
CZ20014226A3 (cs) 2002-03-13
MY135627A (en) 2008-05-30
AU771778B2 (en) 2004-04-01
PL199650B1 (pl) 2008-10-31
ATE337008T1 (de) 2006-09-15
HUP0201275A3 (en) 2004-04-28
SI1185272T1 (en) 2004-12-31
RU2237477C2 (ru) 2004-10-10
BR0010948A (pt) 2002-04-23
DK1410800T3 (da) 2006-12-27
CN101869565A (zh) 2010-10-27
CA2372668C (en) 2009-11-03
EP1410800B1 (en) 2006-08-23
HUP0201275A2 (en) 2002-08-28
NO20015746L (no) 2001-11-26
PT1736158E (pt) 2009-11-11
IL146707A0 (en) 2002-07-25
HK1048444A1 (en) 2003-04-04
KR100683367B1 (ko) 2007-02-15
US20050113386A1 (en) 2005-05-26
US6900212B1 (en) 2005-05-31
KR20020008847A (ko) 2002-01-31
ATE263564T1 (de) 2004-04-15
CA2615271A1 (en) 2000-12-07
MXPA01012172A (es) 2002-07-22
CY1109472T1 (el) 2012-05-23
EP1736158A3 (en) 2007-01-03
EP1185272A2 (en) 2002-03-13
ES2219342T3 (es) 2004-12-01
ES2330774T3 (es) 2009-12-15
WO2000072832A3 (en) 2001-12-20
EP1185272B1 (en) 2004-04-07
PL200490B1 (pl) 2009-01-30
PL199516B1 (pl) 2008-09-30
CN1361692A (zh) 2002-07-31

Similar Documents

Publication Publication Date Title
ATE438399T1 (de) Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4- (2-carbamoylbenzofuran-5-yl)piperazin und dessem physiologisch akzeptablen salzen
DE60040234D1 (de) Automatische erstellung von dokumenten mittels anordnungselement und inhaltselementen
ATE305933T1 (de) Piperazin derivate
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DK1198453T5 (da) N-(indolcarbonyl-)piperazinderivater
ATE267183T1 (de) Piperazine und piperidine derivate
ID24481A (id) Gastrokinetik monosiklik benzamida dari derivat-3-atau-tersubstitusi 4-(aminometil)-piperidin
DE50012379D1 (de) Verwendung von nanoskaligen antischuppenwirkstoffen
ATE301703T1 (de) Verwendung von zusammensetzungen zur textilpflege
NO984380L (no) Nye piperazin og piperidinforbindelser
DK1283838T3 (da) Piperazin- og piperidinforbindelser
NO20042406L (no) Heterosykliske derivater av glysinamid og deres medisinske anvendelse
PT1446399E (pt) Derivados de piperazina tendo actividade antagonista de sst1
EE200200462A (et) Piperidiini ja piperasiiniga asendatud N-hüdroksüformamiidid kui metalloproteinaaside inhibiitorid
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE222456T1 (de) Stabilisierung von isothiazolonen
DE60125374D1 (de) Bisacrylamid enthaltende dentalmassen und deren verwendung
DE60217870D1 (de) Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze
DE60210696D1 (de) Optisch aktive 4-(tert-Butoxycarbonyl)piperazin Derivate und Verfahren zu ihrer Herstellung
DE59904415D1 (de) Verwendung von Moxonidin als Thermogenese stimulierend wirksames Arzneimittel
DE60020583D1 (de) Synchronisierung von pcm und pseudozufallstaktgebern
DE10049604B4 (de) Dielektrische Keramikzusammensetzung und Verwendung derselben
DE60037197D1 (de) Verwendung funktioneller oraler präparate
ATE369859T1 (de) Verwendung von arzneimitteln enthaltend n, n'- disubstituierte piperazin-verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1736158

Country of ref document: EP